Oxford Nanopore Technologies Limited
Oxford Nanopore Technologies plc engages in the research, development, manufacture, and commercialization of a novel generation of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) sequencing technology that allows the real-time analysis of DNA or RNA. It offers MinION Mk 1D, a portable device for DNA and RNA; GridION and GridION Q, a compact bench top device, which delivers a version of hard… Read more
Oxford Nanopore Technologies Limited (ONTTF) - Net Assets
Latest net assets as of June 2025: $523.40 Million USD
Based on the latest financial reports, Oxford Nanopore Technologies Limited (ONTTF) has net assets worth $523.40 Million USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($671.70 Million) and total liabilities ($148.30 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $523.40 Million |
| % of Total Assets | 77.92% |
| Annual Growth Rate | 22.78% |
| 5-Year Change | 215.35% |
| 10-Year Change | 483.51% |
| Growth Volatility | 79.48 |
Oxford Nanopore Technologies Limited - Net Assets Trend (2012–2024)
This chart illustrates how Oxford Nanopore Technologies Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Oxford Nanopore Technologies Limited (2012–2024)
The table below shows the annual net assets of Oxford Nanopore Technologies Limited from 2012 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $586.34 Million | -8.93% |
| 2023-12-31 | $643.85 Million | -7.17% |
| 2022-12-31 | $693.56 Million | -1.48% |
| 2021-12-31 | $703.98 Million | +278.62% |
| 2020-12-31 | $185.93 Million | +69.76% |
| 2019-12-31 | $109.53 Million | -23.35% |
| 2018-12-31 | $142.89 Million | +52.69% |
| 2017-12-31 | $93.58 Million | -35.57% |
| 2016-12-31 | $145.24 Million | +44.54% |
| 2015-12-31 | $100.48 Million | +52.20% |
| 2014-12-31 | $66.02 Million | +0.38% |
| 2013-12-31 | $65.77 Million | +31.71% |
| 2012-12-31 | $49.94 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Oxford Nanopore Technologies Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 34574963100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $96.00K | 0.02% |
| Other Comprehensive Income | $208.51 Million | 35.56% |
| Other Components | $779.70 Million | 132.98% |
| Total Equity | $586.34 Million | 100.00% |
Oxford Nanopore Technologies Limited Competitors by Market Cap
The table below lists competitors of Oxford Nanopore Technologies Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Leonteq AG
PINK:LNTQF
|
$509.56 Million |
|
CMS Info Systems Limited
NSE:CMSINFO
|
$509.57 Million |
|
IPH Ltd
AU:IPH
|
$509.75 Million |
|
Hyundai Development Co
KO:294870
|
$509.77 Million |
|
China Datang Corporation Renewable Power Co. Limited
F:DT7
|
$509.39 Million |
|
Investis Holding S.A.
LSE:0RHV
|
$509.30 Million |
|
Shandong Huatai Paper Industry Shareholding Co Ltd
SHG:600308
|
$509.27 Million |
|
Sanquan Food Co Ltd
SHE:002216
|
$509.19 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Oxford Nanopore Technologies Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 643,851,000 to 586,338,000, a change of -57,513,000 (-8.9%).
- Net loss of 146,188,000 reduced equity.
- New share issuances of 83,233,000 increased equity.
- Other comprehensive income increased equity by 5,580,999.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-146.19 Million | -24.93% |
| Share Issuances | $83.23 Million | +14.2% |
| Other Comprehensive Income | $5.58 Million | +0.95% |
| Other Changes | $-139.00K | -0.02% |
| Total Change | $- | -8.93% |
Book Value vs Market Value Analysis
This analysis compares Oxford Nanopore Technologies Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.96x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $-0.15 | $1.28 | x |
| 2013-12-31 | $0.16 | $1.28 | x |
| 2014-12-31 | $0.15 | $1.28 | x |
| 2015-12-31 | $0.20 | $1.28 | x |
| 2016-12-31 | $0.27 | $1.28 | x |
| 2017-12-31 | $0.17 | $1.28 | x |
| 2018-12-31 | $0.18 | $1.28 | x |
| 2019-12-31 | $0.14 | $1.28 | x |
| 2020-12-31 | $0.23 | $1.28 | x |
| 2021-12-31 | $0.86 | $1.28 | x |
| 2022-12-31 | $0.84 | $1.28 | x |
| 2023-12-31 | $0.77 | $1.28 | x |
| 2024-12-31 | $0.65 | $1.28 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Oxford Nanopore Technologies Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -24.93%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -79.80%
- • Asset Turnover: 0.25x
- • Equity Multiplier: 1.27x
- Recent ROE (-24.93%) is above the historical average (-35.02%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 0.00% | -12816.49% | 0.00x | 0.00x | $-13.54 Million |
| 2013 | -36.93% | 0.00% | 0.00x | 1.05x | $-30.77 Million |
| 2014 | -56.36% | 0.00% | 0.00x | 1.07x | $-43.53 Million |
| 2015 | -38.62% | -5162.33% | 0.01x | 1.09x | $-48.48 Million |
| 2016 | -40.98% | -1304.95% | 0.03x | 1.10x | $-73.52 Million |
| 2017 | -60.41% | -410.07% | 0.12x | 1.27x | $-65.89 Million |
| 2018 | -37.17% | -163.34% | 0.19x | 1.23x | $-67.41 Million |
| 2019 | -65.93% | -138.71% | 0.32x | 1.50x | $-83.17 Million |
| 2020 | -32.94% | -53.79% | 0.40x | 1.51x | $-79.84 Million |
| 2021 | -23.81% | -125.40% | 0.16x | 1.20x | $-238.01 Million |
| 2022 | -13.12% | -45.83% | 0.24x | 1.19x | $-160.38 Million |
| 2023 | -24.00% | -91.06% | 0.22x | 1.21x | $-218.89 Million |
| 2024 | -24.93% | -79.80% | 0.25x | 1.27x | $-204.82 Million |
Industry Comparison
This section compares Oxford Nanopore Technologies Limited's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Oxford Nanopore Technologies Limited (ONTTF) | $523.40 Million | 0.00% | 0.28x | $509.48 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |